Amplified Ingredients Opens Domestic Fulfillment for KSM-66 Ashwagandha

Amplified Ingredients, located in Missouri, has received its first domestic shipment of KSM-66 ashwagandha conventional extract.¹ US.-based fulfillment is now available to brand owners and contract manufacturers, with certified organic KSM-66 expected later this year and exclusive US distribution of ROC KSM-66 for the pet supplement category.

For manufacturers, the announcement addresses a familiar operational constraint, which is that reliance on overseas shipping for a raw material that has become one of the more widely used branded botanicals in the stress-and-mood category.

"We believe that a great ingredient is only as good as the solution it helps create," said Francisco Rodriguez, president at Amplified Ingredients. "Bringing KSM-66 into our domestic warehouse is about more than just supply; it's about providing an anchor for ‘solution stacking.’ We are now able to help our partners combine the stress-management power of KSM-66 with our broader portfolio of heat-stable probiotics, bioavailable minerals, and regenerative glandulars to create products that truly transform health."

What Clinical Evidence Supports Ashwagandha for Stress Management?

The most current evidence synthesis on the ingredient category comes from a 2025 systematic review and meta-analysis pooling 15 randomized controlled trials and 873 participants. That analysis found statistically significant reductions in anxiety and perceived stress scores, along with lower cortisol levels, among adults supplementing with ashwagandha compared with placebo. The same analysis found no significant improvement in quality-of-life measures.²

How Should This Evidence Be Interpreted?

Taken together, the data point to a consistent, moderate signal for stress- and cortisol-related outcomes rather than a settled, uniform effect. Individual trials vary in extract type, dosage, and duration, and much of the published research has been funded or supported by ingredient suppliers, which is a common limitation across the botanical supplement category.

Reviewers have also noted that not every outcome measure responds consistently; the 2025 meta-analysis, for instance, found benefits for stress and anxiety scores but not for broader quality-of-life measures. That distinction matters for manufacturers making formulation and marketing decisions, since the evidence supports specific, measured endpoints rather than general wellness claims.

What Formulation Options Come With the Domestic Inventory?

Amplified Ingredients is offering KSM-66 in 2 particle sizes: an 80-mesh grade suited to encapsulation and a 300-mesh, fine-milled grade intended for gummies and beverages where grit is a formulation concern.

The company is also positioning the ingredient alongside its existing portfolio, which includes a Bacillus subtilis probiotic, glandular ingredients, and peptide-based mineral compounds, as components manufacturers can combine within a single stress-support or general-health formulation.¹ Technical packs with specifications, certificates of analysis, and clinical summaries are available to manufacturers planning production runs.

What Are the Limitations of the Current Research, and What Comes Next?

As a dietary ingredient marketed under the Dietary Supplement Health and Education Act (DSHEA), KSM-66 has not undergone the efficacy review process required of pharmaceutical products, and existing trials remain modest in scale relative to that standard.³

Longer-term safety data, head-to-head comparisons against other ashwagandha extracts, and replication in more diverse populations remain limited. For manufacturers, the more immediate development is logistical rather than clinical—the shift to domestic fulfillment is intended to reduce the sourcing delays that have historically complicated production planning for ashwagandha-containing finished products, with organic-certified inventory anticipated later this year.

References

1. Amplified Ingredients. Amplified Ingredients Announces Arrival of KSM-66 Ashwagandha Inventory; Launches Domestic Fulfillment and Synergistic "Ingredient Solutions" for U.S. Manufacturers. July 16, 2026. Accessed July 20, 2026. Press release provided via email.

2. Bachour G, Samir A, Haddad S, Houssaini MA, El Radad M. Effects of ashwagandha supplements on cortisol, stress, and anxiety levels in adults: a systematic review and meta-analysis. BJPsych Open. 2025;11(suppl 1):S39. doi:10.1192/bjo.2025.10136

3. US Food and Drug Administration. Dietary Supplement Health and Education Act of 1994. Pub L No. 103-417, 108 Stat 4325.